Disclosures Disclosure Policy Panel Member Disclosures Panel Member Disclosures by Meeting Date End User License Agreement

2020年7月13日 · Chemotherapy-induced nausea and vomiting (CINV) have been consistently demonstrated to be among the most feared adverse effects of cancer treatment. 26, 27 Significant progress has been made in limiting CINV through the introduction of several classes of antiemetics and their evidence-based incorporation into antiemetic regimens. 28 ...

2017年7月1日 · The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis are intended to provide an overview of the treatment principles for preventing chemotherapy-induced (or RT-induced) N/V, and to provide recommendations for antiemetic prophylaxis according to the emetogenic potential of antitumor therapies.

2021年8月3日 · NCCN、ASCO和CSCO指南都明确提出 [2-4]：预防性用药是控制CINV的关键，止吐治疗优先应用于抗肿瘤药，选择止吐方案是基于抗肿瘤药物致吐风险等级 ...

Clinical practice guidelines published by NCCN 6 and ASCO 7 have established standard approaches to the prevention of CINV. Each set of guidelines outlines antiemetic treatment according to the emetogenic potential of a given regimen.

Numerous groups have published guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). The current management of CINV, however, remains suboptimal, due in part to poor adherence to existing antiemetic ...

2024年1月18日 · DEX is effective in controlling acute and delayed CINV, with a recommended dose of 12 mg once on day 1 of chemotherapy and 8 mg once daily on days 2, 3, and 4 in guidelines for single-day HEC prophylaxis. 1 - 3 However, the cumulative dose of DEX can reach 216 mg over six cycles of HEC, leading to potential toxicities such as insomnia ...

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this narrative review to compare the latest guidelines …

Low-risk regimens induce CINV in 10% to 30%, and regimens with minimal emetogenic potential cause nausea and/or vomiting in < 10% of these patients (NCCN, 2016). The NCCN Guideline includes dozens of chemotherapeutic agents, organized by emetogenic potential and route of administration (intravenous [Table 1] and oral [Table 2]). Table 1. Table 2.

This session incorporated a case-study approach and interactive dialogue to provide an understanding of current antiemesis guidelines. The program was designed to illustrate ways that nurses can implement evidence-based practice into their daily clinical setting to successfully manage chemotherapy-induced nausea and vomiting.